Sawai Group Holdings Co., Ltd. (4887.T) JPX

1,933.50

+17(+0.89%)

Updated at October 20 10:35AM

Currency In JPY

Sawai Group Holdings Co., Ltd.

Address

5-2-30, Miyahara

Osaka, 532-0003

Japan

Phone

81 6 6105 5818

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

3482

First IPO Date

April 01, 2021

Key Executives

NameTitlePayYear Born
Mr. Mitsuo SawaiChairman, President, Group Chief Executive Officer & Group Chief Operating Officer01956
Mr. Toru TerashimaSenior Executive Officer01959
Mr. Yasushi KoraGeneral Manager of Public Relations & Investor Relations Office0N/A
Mr. Seiji NishimuraCorporate Officer & Group Chief Marketing Officer0N/A
Ms. Nobuko SugimotoGroup Chief Intellectual Property Officer0N/A
Mr. Shoji Yokota Ph.D.Senior Managing Executive Officer, Group Chief Research & Development Officer and Director01957
Mr. Toshiya HasuoGroup Chief Production Officer0N/A
Mr. Motohiko KimuraSenior Managing Executive Officer0N/A
Jun TsujiiGeneral Manager of the Group Finance Department0N/A
Mr. Taku NakaokaCorporate Officer, Group Chief Officer of USA Business & GM of Group Strategy Department0N/A

Description

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.